Pacs Group, INC

PACS Group, Inc. announced the results of its 2026 Annual Meeting of Stockholders, including the election of two directors and the ratification of its independent auditor.

PACS Group, Inc. announced robust first quarter 2026 financial results, exceeding expectations with significant increases in revenue and net income, leading to an upward revision of full-year Adjusted EBITDA guidance.

PACS Group, Inc. has appointed Carey P. Hendrickson as Chief Financial Officer, succeeding co-founder Mark Hancock, who will transition to Vice Chairman of the Board.

PACS Group, Inc. announced the appointment of Dr. Patrick H. Conway, former CMS Deputy Administrator and current CEO of Optum, to its Board of Directors, effective immediately.

PACS Group, a leading post-acute healthcare company, announced robust financial results for fiscal year and fourth quarter 2025, alongside optimistic 2026 guidance.

PACS Group, Inc. announced the results of its 2025 Annual Meeting, where stockholders elected two Class I directors and approved all proposals, including auditor ratification and executive compensation.

PACS Group, Inc. announced a significant increase in revenue and operating income for the second quarter of 2026, driven by facility expansion and improved occupancy, while also disclosing ongoing regulatory investigations and material weaknesses in internal controls.

PACS Group, Inc. announces significant revenue growth and improved profitability in its first quarter of 2026, driven by increased patient days and occupancy rates.

PACS Group announced significant revenue and net income increases for Q3 2025, alongside ongoing regulatory investigations and identified material weaknesses in internal controls.

PACS Group reported significant revenue and net income increases for Q2 2025, driven by facility expansion, but faces multiple ongoing regulatory and legal investigations, material weaknesses in internal controls, and credit facility forbearance.

PACS Group reports significant revenue growth in Q1 2025, driven by facility expansion, but faces ongoing SEC and DOJ investigations and internal control weaknesses.

PACS Group restates prior financial statements, reveals material weaknesses in internal controls, and faces multiple government and SEC investigations, alongside a CFO resignation.

PACS Group, a leading post-acute healthcare provider, announced significant revenue and net income growth for 2025, while navigating multiple ongoing regulatory and legal investigations.

PACS Group, Inc. has restated prior financial statements and identified material weaknesses in internal controls following an independent Audit Committee investigation into allegations from a short seller report.

Joshua Jergensen, President & COO of PACS Group, Inc., sold 40,000 shares of common stock on July 15, 2026.

Mark Hancock, a Director and 10% owner of PACS Group, Inc., sold 13,628 shares of common stock on July 14, 2026.

Mark Hancock, a Director and 10% Owner of PACS Group, Inc., reported the sale of common stock totaling 25,304 shares through a pre-arranged Rule 10b5-1 trading plan.

Michelle Renee Lewis, Chief Accounting Officer of PACS Group, Inc., has reported the sale of company stock totaling over 14,000 shares across three transactions executed between July 1st and July 6th, 2026, under a pre-established Rule 10b5-1 trading plan.

PACS Group, Inc. Director Mark Hancock reported transactions involving the sale of common stock, executed under a pre-arranged Rule 10b5-1 trading plan.

Director Patrick Conway acquired 4,287 shares of PACS Group common stock through restricted stock units.

PACS Group, Inc. has announced its 2026 Annual Meeting of Stockholders, scheduled for June 10, 2026, a virtual event, and has proposed the re-election of two Class II directors.

PACS Group, Inc. announces its 2025 Annual Meeting of Stockholders, outlining key proposals including director elections and executive compensation votes, while also addressing a prior financial restatement and related compensation clawbacks.

PACS Group, Inc. has filed a registration statement to increase the number of shares offered in its initial public offering by approximately $120.1 million.

PACS Group, a leading post-acute healthcare company, is undertaking a secondary offering of common stock to repay debt and support future expansion.

PACS Group, Inc. has filed an S-1 amendment to register an additional 2,735,357 shares of common stock, including an underwriter option, representing no more than 20% of the initial offering price.

PACS Group, a leading post-acute healthcare company, has filed an amendment to its S-1 registration statement for an initial public offering of 19,050,000 shares of common stock, with plans to list on the NYSE under the symbol PACS.

PACS Group, Inc. files an amendment to its S-1 registration statement, detailing changes to its bylaws and confirming its application to list on the NYSE under the ticker symbol 'PACS'.

PACS Group, a leading post-acute healthcare company, has filed an amendment to its S-1 registration statement for an initial public offering of its common stock, with plans to list on the New York Stock Exchange under the symbol PACS.

Mark Hancock has filed an amended Schedule 13G, disclosing beneficial ownership of 54,626,199 shares, representing 35.2% of PACS Group, Inc.'s common stock as of December 31, 2024.

Jason Hulse Murray, an insider at PACS Group, Inc., has disclosed beneficial ownership of 35.2% of the company's common stock as of December 31, 2024, in an amended Schedule 13G filing.